The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
 
Jeremy S. Abramson
Consulting or Advisory Role - Abbvie; Alimera Sciences; Alimera Sciences; Bayer; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Gilead Sciences; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Merck; MorphoSys; Novartis; Verastem
Research Funding - AI Therapeutics (Inst); Celgene (Inst); Seagen (Inst)
 
Tanya Siddiqi
Consulting or Advisory Role - AstraZeneca; BeiGene; Juno Therapeutics; Pharmacyclics
Speakers' Bureau - Pharmacyclics/Janssen; Seagen
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Juno Therapeutics
 
Leo I. Gordon
Consulting or Advisory Role - Bayer; Gilead Sciences; Juno Therapeutics
Patents, Royalties, Other Intellectual Property - Zylem
 
Matthew Alexander Lunning
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen Oncology; Juno Therapeutics; Kite, a Gilead company; Novartis; Pharmacyclics; Seagen; Spectrum Pharmaceuticals; TG Therapeutics; Verastem
Research Funding - Celgene (Inst); Celgene (Inst); Celgene (Inst); Curis (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Juno Therapeutics (Inst); miRagen (Inst); TG Therapeutics (Inst); TG Therapeutics (Inst)
 
Michael Wang
Stock and Other Ownership Interests - More Health
Honoraria - AstraZeneca; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries; Onclive; oncology business review; Peerview; Pharmacyclics; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; AxImmune; Bioinvent; Celgene; Guidepoint Global; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; More Health; Noble Insights; Pharmacyclics/Janssen; Pulse Biosciences
Research Funding - Acerta Pharma; Amgen; AstraZeneca; BeiGene; Bioinvent; Celgene; Janssen Research & Development; Juno Therapeutics; Kite, a Gilead company; Loxo; Novartis; Oncternal Therapeutics; Pharmacyclics; VelosBio; Verastem
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Dava Oncology; Janssen Research & Development; OM Pharmaceutical Industries
 
Jon E. Arnason
Consulting or Advisory Role - Celgene; Regeneron
Research Funding - Celgene (Inst); Jazz Pharmaceuticals (Inst); Loxo (Inst); Regeneron (Inst)
 
Amitkumar N. Mehta
Stock and Other Ownership Interests - Witty Health
Consulting or Advisory Role - Aileron Therapeutics; Bristol-Myers Squibb; Carevive; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals
Speakers' Bureau - AstraZeneca; Gilead Sciences; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals
Research Funding - ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Carevive (Inst); Epizyme (Inst); Forty Seven (Inst); Gilead Sciences (Inst); incyte (Inst); Juno Therapeutics (Inst); Merck (Inst); oncotartis (Inst); Pharmacyclics/Janssen (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst)
 
Enkhee Purev
Employment - Genentech
 
David G. Maloney
Consulting or Advisory Role - Celgene; Eureka Therapeutics; Genentech/Roche; Gilead Sciences; Kite, a Gilead company; Novartis
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on 4 provisional patents.
 
Charalambos Andreadis
Employment - Genentech (I)
Stock and Other Ownership Interests - Roche/Genentech (I)
Consulting or Advisory Role - Astellas Pharma; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis
Research Funding - Amgen; Celgene; Cellerant; GlaxoSmithKline; Juno Therapeutics; Karyopharm Therapeutics; Merck; Novartis
Travel, Accommodations, Expenses - Bayer; Celgene; Genentech; Gilead Sciences; Jazz Pharmaceuticals; Kite, a Gilead company; Novartis
 
Alison R. Sehgal
Research Funding - Juno Therapeutics; Kite/Gilead; Merck
 
Scott R. Solomon
Speakers' Bureau - Kite/Gilead (Inst)
 
Nilanjan Ghosh
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Juno Therapeutics; Kite, a Gilead company; Seagen; Spectrum Pharmaceuticals; TG Therapeutics
Speakers' Bureau - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen Oncology; Kite/Gilead; Seagen
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
Tina M. Albertson
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Juno Therapeutics
 
Jacob Garcia
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Juno Therapeutics
 
Ana Kostic
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Celgene; Juno Therapeutics; Seagen
 
Daniel Li
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; Gilead Sciences
 
Yeonhee Kim
Employment - Juno Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Maria Lia Palomba
Stock and Other Ownership Interests - Seres Therapeutics (I)
Honoraria - Amgen (I); Celgene; Evelo Therapeutics (I); Flagship Biosciences (I); Jazz Pharmaceuticals (I); Merck; Merck (I); Novartis (I); Pharmacyclics; Seres Therapeutics (I); Therakos (I)
Consulting or Advisory Role - Amgen (I); Celgene; Evelo Therapeutics (I); Flagship Biosciences (I); Jazz Pharmaceuticals (I); Kite, a Gilead company; Merck; Merck (I); Novartis; Novartis (I); Seres Therapeutics (I); Therakos (I)
Research Funding - Seres Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Intellectual Property Rights (I); Juno intellectual property rights (Inst)